CVM Announces the Availability of the NARMS 2010 Executive Report
July 23, 2012
The Food and Drug Administration’s Center for Veterinary Medicine (CVM) announced today the availability of the National Antimicrobial Resistance Monitoring System—Enteric Bacteria (NARMS) 2010 Executive Report.
The annual Executive Report summarizes, in an integrated format, NARMS data on non-typhoidal Salmonella and Campylobacter isolates recovered in 2010 from human clinical cases, retail meats, and food animals at federally inspected slaughter and processing plants. The report also includes susceptibility data on Escherichia coli isolates recovered from retail meats and chickens. Summary data from prior years are also included.
NARMS, in partnership with the Centers for Disease Control and Prevention (CDC) and the U.S. Department of Agriculture (USDA), is a national public health surveillance system that tracks antibiotic resistance in foodborne bacteria. Under the NARMS program, samples are collected from human, animal and retail meat sources, and tested for bacteria that are resistant to various antibiotics used in human and veterinary medicine.
Scientists examine the data for changes in the proportion of bacteria that are resistant to different antibiotics. The NARMS program assists the agency in making data-driven decisions on the approval of safe and effective antimicrobial drugs for animals.
The NARMS 2010 Executive Report is very similar to the 2009 report. The main change is the addition of a separate summary highlighting the most important trends among Salmonella and Campylobacter data. Other changes include:
- Tables highlighting the resistance profile of the top Salmonella serotypes are now grouped by like sources (e.g. retail chicken breasts and chickens at slaughter, etc).
- Multidrug resistance data for Campylobacter jejuni and coli are now reported in one table instead of two.
- Due to space constraints, data from years 1996-1998 are not included in the antimicrobial resistance tables. Data from these years are still displayed in the graphs and supporting tables. Readers can refer to the NARMS 2007 Executive Report for the data from those years.
- Added Appendix C, which highlights the impact of the new breakpoints for ciprofloxacin, which will be applied to non-typhoidal Salmonella in all 2011 NARMS reports.
As a supplement to the report, CVM has also provided three interactive graphs. The three graphs allow users to visualize trends in antimicrobial resistance among NARMS non- typhoidal Salmonella, the top five Salmonella serotypes isolated from humans, and Campylobacter isolates through a user-friendly interface.